Myomo

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. It offers MyoPro, an upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myomo reports 9% revenue growth in Q1 2024 earnings call

Myomo's Q1 2024 performance reflects revenue growth driven by favorable CMS developments, with plans to double manufacturing capacity and achieve cash flow breakeven by Q4 2024.
The company's strategic strengths lie in its focus on the prevalence group, international expansion, and commitment to market leadership through increased output and R&D investments.
Challenges include managing operating expenses, scaling manufacturing capacity, and meeting revenue targets amidst market competition and reimbursement rate fluctuations.
Opportunities abound in international growth, market expansion in Germany, and the potential for accelerated U.S. revenue, supported by investments in resources and R&D.

Myomo excels in Q2 with record revenues and global expansion

Myomo's Q2 2024 performance reflects strong revenue growth, operational efficiency gains, and strategic expansion initiatives.
The company's strengths lie in international revenue generation, production facility expansion plans, and commitment to meeting product demand.
Challenges include scaling production while ensuring quality, monitoring advertising ROI, and balancing R&D with operational needs.
Opportunities arise from investor engagement, increased advertising, and continued innovation to drive market presence and revenue growth.

Myomo reports record Q3 revenue, eyes global expansion and market partnerships

Myomo's Q3 performance showcased robust revenue growth, pipeline expansion, and strategic partnerships, positioning the company for sustained success and global expansion.
While facing operational losses, Myomo's strengths in product innovation, market expansion, and capacity planning provide a solid foundation for future growth and profitability.
Challenges in cost management, market penetration, and regulatory compliance need to be addressed, but the company's proactive approach to expansion and partnerships bodes well for seizing growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The firm is also involved in selling products through various other sales channels including through orthotics and prosthetics providers, veterans’ administration, and to distributors in certain accounts and geographic markets. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.

BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses.

Myomo Announces Closing of $6.5 Million Upsized Public Offering

BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses.

Myomo Announces Pricing of $6.5 Million Upsized Public Offering

BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced a reduction in force for the purpose of improving operating efficiency in its direct billing channel and reduce its cash burn. The action today involved the elimination of approximately 12% of its workforce, impacting employees in its call center and administrative functions. This action and other cost reductions being undertaken by the Company are expected to save in excess of $2 million on an annual basis.

Myomo Announces Initiative to Reduce Cash Burn

BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported progress and next steps in the process to obtain Medicare Part B reimbursement for the MyoPro® as a brace from the Centers for Medicare & Medicaid Services (CMS).

Myomo Provides Update on Progress to Obtain Medicare Part B Reimbursement for MyoPro

BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that in an appeal before the Berlin-Brandenburg Regional Social Court (L 9 KR 210/21), the court confirmed that the MyoPro powered whole-arm orthosis is an orthopedic aid that serves to directly compensate for disabilities. As a result of this ruling, the third-largest German health insurance company, DAK, has been ordered to cover the costs for the MyoPro for the plaintiff.

Ruling by German Social Court Supports MyoPro Reimbursement by Nation's Statutory Health Insurance System

Myomo, Inc. (NYSE:MYO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Jim Sidoti - Sidoti & Company Edward Woo - Ascendiant Capital Operator Welcome to the Myomo Incorporated Third Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode.

Myomo, Inc. (MYO) Q3 2022 Earnings Call Transcript

BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2022.

Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2022 on November 10, 2022, after the market close.

Myomo to Report Third Quarter Financial Results on November 10, 2022

BOSTON, MA / ACCESSWIRE / October 5, 2022 / Myomo, Inc. (NYSE American:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo's chairman and chief executive officer, will present at the Microcap Rodeo presents The Windy City Roundup 2022 conference, which is being held live, in-person on October 12th - 13th, 2022. Mr. Gudonis is scheduled to present on October 12 at 9:30 a.m.

Myomo To Present at the MicroCap Rodeo Presents The Windy City Roundup 2022

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference. The Conference is being held September 12 – 14, both virtually and in New York City. Paul Gudonis, chief executive officer, and David Henry, chief financial

Myomo to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced receipt of a $120,000 order for MyoPro® units from Cleveland's Louis Stokes Veterans Administration (“VA”) Medical Center. The units will be used in an investigator-initiated, randomized clinical trial led by Svetlana Pundik, M.D., Assistant Professor

Myomo Receives Order from the Louis Stokes Cleveland VA Medical Center to Support MyoPro Clinical Trial

Myomo, Inc. (NYSE:MYO ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Scott Henry - Roth Capital Jim Sidoti - Sidoti & Company Ed Woo - Ascendiant Capital Operator Good day and welcome to the Myomo Incorporated Second Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode.

Myomo, Inc.'s (MYO) CEO Paul Gudonis on Q2 2022 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2022. Financial and operational highlights for the second quarter of 2022 include the following: Product revenue was $3.7 million, up 18% from Q2 2021 and up 28% sequentially; A record 420

Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2022 on August 3, 2022, after the market close. The Company will host a conference call the same day, Wednesday, August 3, 2022 at 4:30 p.m. ET with prepared remarks by

Myomo to Report Second Quarter Financial Results on August 3, 2022

Myomo, Inc. (MYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Makes Myomo, Inc. (MYO) a New Strong Buy Stock

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter. Revenue for the second quarter of 2022 is expected to be $3.4 million to $3.6 million, an increase of 10% to 16% compared with the second quarter of 2021.

Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo's chairman and chief executive officer, and David Henry, Myomo's chief financial officer, will present and provide a business update at the Sidoti Summer Small Cap Conference, which is being held virtually from June 15 to June

Myomo To Present at the Sidoti Summer Small Cap Virtual Investor Conference

Myomo, Inc. (NYSE:MYO ) Q1 2022 Results Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Kim Golodetz - IR, LHA Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Scott Henry - Roth Capital Ben Haynor - Alliance Global Partners Jim Sidoti - Sidoti & Company Paul Nouri - Noble Equity Operator Good afternoon. And welcome to the Myomo Incorporated First Quarter 2022 Earnings Conference Call.

Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2022 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months ended March 31, 2022. Financial and operational highlights for the first quarter of 2022 include the following (all comparisons are with the first quarter of 2021, unless otherwise noted): Revenue was $3.9 millio

Myomo Reports First Quarter 2022 Financial Results

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2022 on May 11, 2022 after the market close. The Company will host a conference call the same day, Wednesday, May 11, 2022 at 4:30 p.m. ET with prepared remarks by Paul R. Gudo

Myomo to Report First Quarter Financial Results on May 11, 2022

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, provides an update on the status of its joint venture (“JV”) in China and the associated impact on first quarter 2022 revenue. As of March 31, 2022, a portion of the technology license fee from the JV Company, Jiangxi Myomo Medical Assistive Appliance Co. Ltd., has b

Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee

Myomo, Inc. (MYO) CEO Paul Gudonis on Q4 2021 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will participate in two investor conferences during March: 34th Annual ROTH Conference, March 13-15, 2022 at The Ritz-Carlton, Laguna Niguel, CA. Management will participate in a “Fireside Chat” on Monday, March 14th at 2:00 p.m. PT and will

Myomo To Participate in Two March Investor Conferences

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2021. Financial and operational highlights for the fourth quarter of 2021 include the following (all comparisons are with the fourth quarter of 2020, unless otherwise noted): Revenue w

Myomo Reports Fourth Quarter and Full Year 2021 Financial Results

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and fiscal year ended December 31, 2021 on March 9, 2022 after the market close. The Company will host a conference call the same day, Wednesday, March 9, 2022 at 4:30 p.m. ET with prepared re

News for Myomo Stock (MYO)